This review concluded that differences between conventional insulins and insulin analogues were minimal for the management of type 1, type 2 and gestational diabetes mellitus. Overall, the authors' conclusions were supported by the evidence presented, but caution is advised given the limitations of the included evidence and, in particular, the poor quality of the included trials.
Included interventions were single agent or combination treatments including: rapid-acting analogues (insulin lispro and insulin aspart) or long-acting insulin analogues (insulin glargine and insulin detemir); human insulin; and/or neutral protamine Hagedorn insulin. The majority of trials were in adults and most commonly assessed rapid-acting insulin analogues. Similar numbers of trials in children and adolescents assessed rapid-acting and long-acting insulin analogues. Trial duration ranged from four weeks to 30 months.
An undisclosed number of reviewers independently selected trials for inclusion in the review

Assessment of study quality
Trial quality was assessed using a modified Jadad scale, which assesses allocation concealment, blinding of assessors and the use of an intention-to-treat analysis. Each trial was awarded a score up to a maximum of 5 points.
Two reviewers independently assessed the quality of each study and any discrepancies were resolved through consensus or a third reviewer. standard deviation were extracted. For dichotomous outcomes, relative risks with 95% confidence intervals were calculated.
Methods of synthesis
Trials were grouped according to the type of diabetes (gestational diabetes, paediatric type 1, adult type 1, paediatric type and adult type 2 diabetes) and weighted mean differences or pooled relative risks, with 95% confidence intervals, calculated using a random-effects model. Additional analyses were performed for different methods of administration for rapid-acting insulin analogues, type of bolus insulin administered with long-acting analogues; and the type of oral anti-diabetic agent administered with long-acting insulin analogues in the management of type 2 diabetes.
Statistical heterogeneity was assessed using the I 2 statistic; any value over 50% was investigated further to try to determine possible causes for the observed heterogeneity. Data for premixed insulins and data for bolus insulins were included in the same meta-analyses. Where cross-over trials reported no evidence of carry-over effects, data were combined from both cross-over and parallel trials. The effect of trial quality was also assessed. Where analyses included five or more trials, the risk of publication bias was assessed using funnel plots.
Results of the review
Sixty-eight RCTs were included in the analysis of rapid-acting insulin analogues and 49 RCTs in the analysis of longacting insulin analogues. Sample sizes ranged from 7 to 1,008. Most of the trials were of short to medium duration; the methodological quality was rated as poor (Jadad score 2 or 3).
Rapid-acting insulin analogues: In adults with type 1 diabetes, minimal differences were reported between rapid-acting insulin analogues and regular human insulin for haemoglobin A1c: for insulin lispro the weighted mean difference was -0.09% (95% confidence interval (CI):-0.16 to -0.02; 22 RCTs); for insulin aspart the weighted mean difference was -0.13% (95% CI: -0.20 to -0.07; seven RCTs). Similar differences were reported for patients with type 2 diabetes: for insulin lispro the weighted mean difference was -0.03% (95% CI: -0.12 to -0.06; 11 RCTs); for insulin aspart the weighted mean difference was -0.09% (95% CI: -0.21 to 0.04; six RCTs).
Long-acting insulin analogues: Only marginal differences between long-acting insulin analogues and neutral protamine Hagedorn insulin were reported for haemoglobin A1c in adults with type 1 diabetes: for insulin glargine weighted mean difference was -0.11% (95% CI: -0.21%, -0.02%; 11 RCTs); for insulin detemir weighted mean difference was -0.06% (95% CI: -0.13%, 0.02%, seven RCTs). Among adults with type 2 diabetes: insulin glargine weighted mean difference was -0.05% (95% CI: -0.13 to 0.04; nine RCTs); insulin detemir weighted mean difference was 0.13% (95% CI: 0.03%, 0.22%); three RCTs. No significant evidence of statistical heterogeneity was found.
No statistically significant differences or only very small differences between insulin analogues and conventional insulins, were reported for outcomes assessed in children and adolescents (11 RCTs) and in pregnant women (four RCTs).
Data relating to the incidence of hypoglycaemia were inconsistent. There were insufficient data to assess the effects of different types of insulin on long-term diabetes-related complications or death. There were no significant differences in the incidence of adverse events between insulin analogues and conventional insulins; the most commonly reported adverse events were upper respiratory tract infections, injection site reactions and weight gain.
Further results were reported in the review and appendices.
Cost information
A related assessment of the cost-effectiveness of conventional insulins versus insulin analogues was published elsewhere (see Other Publications of Related Interest field for bibliographic details).
